A combination vial pairing two complementary growth hormone secretagogues — a GHRH analogue paired with a selective GHRP. CJC-1295 prompts the pituitary to increase growth hormone output in a natural pulse rhythm; ipamorelin triggers that pulse through a separate receptor pathway, without raising cortisol or prolactin. Together they produce a stronger, more sustained GH release than either compound alone.
CJC-1295 (No DAC) activates GHRH receptors in the pituitary; ipamorelin activates the ghrelin receptor (GHSR). The dual-pathway GH stimulation produces a physiological pulsatile release without elevating cortisol, prolactin, or ACTH. The 10mg vial suits users who dose twice daily, run extended 12–16 week cycles, or want fewer reconstitutions across a protocol.
Growth hormone and IGF-1 rise in a pulsatile pattern. Lean mass increases, fat mobilises, sleep architecture improves, and recovery accelerates. The larger vial format reduces the number of reconstitutions required across a full cycle.
GH-driven anabolism + BPC-157 tissue repair creates a powerful recovery stack
Adds GHRH stimulation — use under guidance as GH elevation compounds
Systemic tissue healing amplifies the recovery benefits of GH secretagogue protocols
Not medical advice. Not a substitute for medical care. Consult your licensed practitioner before beginning any protocol. Peptides are sold for research purposes only and are suitable for adults aged 18 years and over.